Business Context and Reporting Period
Company: Bright Minds Biosciences Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter ended March 31, 2026 (Six-month interim period)
Filing Date: May 19, 2026
This filing incorporates by reference the Condensed Interim Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the six months ended March 31, 2026, via Exhibits 99.1 and 99.2.
Key Financial Metrics
The provided text contains only the cover page and signature block of the Form 6-K. It does not include the actual financial data from the incorporated exhibits. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
No material changes versus the prior comparable period can be identified from the provided text, as the comparative financial data is located in the incorporated exhibits (99.1 and 99.2) which are not included in the input.
Guidance, Outlook, and Risks
The cover page does not contain management commentary, guidance, outlook, or specific risk factors. These disclosures are expected to be found in Exhibit 99.2 (MD&A), which is referenced but not provided in the input text.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual Condensed Interim Consolidated Financial Statements to verify revenue, cash burn, and liquidity positions.
- Review Exhibit 99.2 for Management's Discussion and Analysis to understand operational progress, clinical trial updates, and forward-looking guidance.
- Verify the status of the registration statements on Form F-3 (File Nos. 333-284694 and 333-289851) referenced in the incorporation by reference section.
- Confirm the certifications provided by the CEO and CFO in Exhibits 99.3 and 99.4.